Tvardi Therapeutics, Inc. — Form D/A
Tvardi Therapeutics, Inc. of HOUSTON, TX, a company, filed a Form D amendment with the SEC on 2018-07-30. The offering totals $8.5M, of which $5.6M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2018-07-30
- Form: D/A
- Accession: 0001742947-18-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $8.5M
- Amount sold: $5.6M
- Remaining: $2.9M
- Investors: 8
- Date of first sale: 2018-06-04
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-314170
Issuer
- Name: Tvardi Therapeutics, Inc.
- CIK: 0001742947
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 2450 Holcombe Boulevard, HOUSTON, TX, 77021
- Phone: 832-413-1362
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Ronald J DePinho | Director | Houston, TX |
| David J Tweardy | Director | Houston, TX |
| David J Tweardy | Executive Officer | Houston, TX |
| Wallace Hall | Director | Beaverton, OR |
| Michael Wyzga | Director | Boston, MA |
| Jamie McNab | Director | Houston, TX |
| Imran Alibhai | Director | Houston, TX |
| Imran Alibhai | Executive Officer | Houston, TX |
| Sujal Shah | Director | BOSTON, MA |
Other filings by this issuer (2)
More